April 17 (Reuters) - Generic drugmaker Mylan NV moved quickly on Friday to pour cold water on published reports that Teva Pharmaceuticals Industries is considering a bid to acquire it.
Mylan last week announced a $29 billion offer to buy Perrigo Co Plc in a move that some analysts suggested was a tactic to help fend off an acquisition by larger rival Teva.
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle15
14:49 Trump warns of ‘retribution’ for companies that offshore jobs, threatening 35 percent tariff14
20:37 Brazil grants antitrust approval for FMC Technologies, Technip merger19
14:45 Spain raises taxes to try to meet EU deficit target13